TheraRadar
← Back
Data updated: Jun 28, 2026

SALIX PHARMS

Big Pharma

SALIX PHARMS is a major pharmaceutical company focused on Gastroenterology, Oncology.

1961
Since
9
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules

SALIX PHARMS's Key Drugs

SALIX PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SALIX PHARMS's Recent FDA Approvals

New NDA/BLA approvals for SALIX PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SALIX PHARMS's Therapeutic Areas

SALIX PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Gastroenterology and Oncology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 50%
1 drugs
Oncology 50%
1 drugs

SALIX PHARMS's Top Competitors

SALIX PHARMS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SALIX PHARMS Pipeline Snapshot

Active clinical trials for SALIX PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis
View revenue breakdown →

Trial Catalysts

  • Gastroenterology pipeline focus
  • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis
View patent timeline →

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Compare with competitor →
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling